Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. (IMNN) generates frequent news as a clinical-stage biotechnology company advancing DNA-mediated immunotherapies and DNA vaccine technologies. Most coverage centers on its lead program, IMNN-001, a TheraPlas-based IL-12 DNA immunotherapy in Phase 3 development for newly diagnosed advanced ovarian cancer, and on its PlaCCine DNA vaccine platform, including the IMNN-101 COVID-19 booster candidate.
Investors following IMNN news can expect regular updates on clinical trial progress, such as enrollment milestones, translational data and survival outcomes from the OVATION 2 Phase 2 study and the pivotal OVATION 3 Phase 3 trial. Company releases describe how IMNN-001 is being evaluated in combination with standard neoadjuvant and adjuvant chemotherapy, and how biomarker data show shifts in the tumor microenvironment toward more active anti-tumor immunity.
Another major news theme is scientific and medical conference activity. Imunon frequently announces posters and presentations at meetings such as the Society for Immunotherapy of Cancer, the European Society for Medical Oncology, the International Gynecologic Cancer Society and specialized ovarian cancer conferences. These items often include new translational data on immune cell changes, cytokine profiles and clinical outcomes associated with IMNN-001.
Imunon also issues news on corporate and financial developments, including quarterly financial results, R&D Day events, capital markets transactions like registered direct offerings and at-the-market equity programs, and Nasdaq listing-related updates. For the PlaCCine platform, news items highlight proof-of-concept data for IMNN-101 and presentations at international vaccine conferences.
For readers tracking IMNN, this news feed provides a consolidated view of clinical milestones, scientific recognition, financing activities and regulatory communications that shape the company’s development trajectory in oncology and DNA vaccine research.
Imunon, Inc. (NASDAQ: IMNN) will hold a conference call on November 14, 2022, at 11:00 a.m. ET to report third-quarter financial results for the period ending September 30, 2022. The company will also update on its clinical development of GEN-1, a DNA-based immunotherapy for advanced ovarian cancer currently in Phase II trials, and its preclinical studies of PLACCINE, aimed at advancing vaccine technology.
Join the call by dialing 866-777-2509 or access it via imunon.com.
Imunon, Inc. (NASDAQ: IMNN) has appointed James E. Dentzer to its Board of Directors as of October 3, 2022. Dentzer, CEO of Curis, Inc., brings over 20 years of biopharmaceutical experience, enhancing the Board to nine members. His leadership experience includes roles at Dicerna and Valeritas. Dentzer aims to support Imunon's clinical programs in immune-oncology and infectious diseases, particularly the advanced development of GEN-1 for ovarian cancer.
Imunon, Inc. (NASDAQ: IMNN) reports promising partial results from a non-human primate study evaluating its PLACCINE vaccine as a potential alternative to mRNA vaccines. In the study, Cynomolgus monkeys showed comparable immunogenicity and viral clearance after vaccination with PLACCINE and a commercial mRNA vaccine. The PLACCINE technology, which uses a synthetic DNA delivery system, demonstrated stability and potential safety advantages. The study underlines the capability of PLACCINE to target viral mutations and enhances efficacy through potent immune modifiers.
Imunon, Inc. (NASDAQ: IMNN) announced that its Compensation Committee approved the grant of inducement stock options and restricted stock grants to two new hires during Q3 2022. The stock options allow purchasing 8,500 shares at an exercise price of $1.65, equal to its closing stock price on September 27, 2022. Vesting occurs in thirds over three years, fully exercisable by September 2025. The restricted stock grants total 2,250 shares, vesting on the one-year anniversary of each employee's start date.
Imunon (NASDAQ: IMNN) announced CEO Dr. Corinne Le Goff will present at the Chardan 6th Annual Genetic Medicines Conference on October 3-4, 2022, in New York City. Dr. Le Goff's presentation is scheduled for October 3 at 2:30 PM ET, and it will be available live and on-demand. Imunon is a clinical-stage biotechnology company developing innovative treatments using its two platforms: TheraPlas for immunotherapies and PLACCINE for nucleic acid vaccines. The company is focused on addressing advanced ovarian cancer with its lead program, GEN-1.